Alveolus Bio
Alveolus Bio is a pioneering biotechnology company focused on developing breakthrough FDA-approved therapeutics for lung diseases. The company leverages its proprietary resMIT platform to deliver targeted bacteria directly to the lungs, aiming to address fibroblast dysfunction in conditions like Idiopathic Pulmonary Fibrosis (IPF) and neutrophilic inflammation. With a strong pipeline of live biotherapeutics and small molecule therapies, Alveolus Bio is committed to revolutionizing the standard of care for chronic respiratory diseases.
Industries
Nr. of Employees
small (1-50)
Alveolus Bio
Products
Preclinical inhaled live biotherapeutic candidates
Live microbiota-based inhaled therapeutic candidates in preclinical/pre-IND stages developed for chronic and neutrophilic inflammatory lung diseases. Programs target idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), non-cystic fibrosis bronchiectasis (NCFBE) and neutrophilic asthma; additional indications referenced include pulmonary arterial hypertension (PAH) and acute respiratory distress syndrome (ARDS).
Preclinical inhaled live biotherapeutic candidates
Live microbiota-based inhaled therapeutic candidates in preclinical/pre-IND stages developed for chronic and neutrophilic inflammatory lung diseases. Programs target idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), non-cystic fibrosis bronchiectasis (NCFBE) and neutrophilic asthma; additional indications referenced include pulmonary arterial hypertension (PAH) and acute respiratory distress syndrome (ARDS).
Services
Support for discovery and mechanistic preclinical studies in respiratory disease using in vitro assays and animal models.
Microbial community profiling from airway samples and metabolomic pathway analysis to identify disease-associated signatures and candidate biomarkers.
Regulatory planning and preparation support for progressing preclinical candidates toward IND submission and clinical development.
Advisory services covering CMC, formulation and drug delivery considerations for inhaled products, leveraging internal and external subject-matter advisors.
Support for discovery and mechanistic preclinical studies in respiratory disease using in vitro assays and animal models.
Microbial community profiling from airway samples and metabolomic pathway analysis to identify disease-associated signatures and candidate biomarkers.
Regulatory planning and preparation support for progressing preclinical candidates toward IND submission and clinical development.
Advisory services covering CMC, formulation and drug delivery considerations for inhaled products, leveraging internal and external subject-matter advisors.
Expertise Areas
- Pulmonary microbiome research
- Inhaled live biotherapeutic development
- Preclinical translational research (in vivo and in vitro)
- Metagenomics and metabolomics for airway samples
Key Technologies
- Inhalation/aerosol pulmonary delivery
- Live biotherapeutic product development
- 16S rRNA sequencing and predicted metagenomics
- Untargeted mass spectrometry metabolomics
News & Updates
Alveolus Bio announced that Dr. Vivek Lal, Founder & CEO, will present at the 2022 BIO CEO & Investor Conference in NYC on February 14-15 and virtually.
Alveolus Bio announced it will present virtually at the Biotech Showcase™ 2022 conference during JP Morgan Healthcare Week.
Research indicates early life inflammation can increase COPD risk, with neutrophil elastase playing a key role.
Differences in airway microbiome and metabolome at birth may influence BPD risk in preterm infants.
Investigation into the presence and diversity of airway microbiome at birth and its potential link to lung disease.
Alveolus Bio announced that Dr. Vivek Lal, Founder & CEO, will present at the 2022 BIO CEO & Investor Conference in NYC on February 14-15 and virtually.
Alveolus Bio announced it will present virtually at the Biotech Showcase™ 2022 conference during JP Morgan Healthcare Week.
Research indicates early life inflammation can increase COPD risk, with neutrophil elastase playing a key role.
Differences in airway microbiome and metabolome at birth may influence BPD risk in preterm infants.
Investigation into the presence and diversity of airway microbiome at birth and its potential link to lung disease.